Bibliography
- FITZGERALD GA: COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat. Rev. Drug Discov. (2003) 2(11):879–890.
- ••An excellent review covering prostaglandinbiology and the development of COX-2-selective inhibitors.
- PATRONO C, PATRIGNANI P, GARCIARODRIGUEZ LA: Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J. Clin. Invest. (2001) 108(1):7–13.
- BOMBARDIER C, LAINE L, REICIN A et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in Patients with rheumatoid arthritis. VIGOR Study Group. N Engl. J. Med. (2000) 343(21):1520–1528.
- •The first clinical epidemiological study to trigger concerns over selective COX-2 inhibitors.
- BONVENTRE JV, HUANG Z, TAHERI MR, O'LEARY E, LI E, MOSKOWITZ MA, SAPIRSTEIN A: Reduced fertility and postischaemic brain injury in mice deficient in cytosolic phospholipase A2. Nature (1997) 390(6660):622–625.
- SAPIRSTEIN A, BONVENTRE JV: Specific physiological roles of cytosolic phospholipase A(2) as defined by gene knockouts. Biochim. Biophys. Acta. (2000) 1488(1-2):139–148.
- MCKEW JC, LOVERING F, CLARK JD et al.: Structure-activity relationships of indole cytosolic phospholipase A(2)alpha inhibitors: substrate mimetics. Bioorg-. Med. Chem. Lett. (2003) 13(24):4501–4504.
- ARIMURA A, YASUI K, KISHINO J et al.: Prevention of allergic inflammation by a novel prostaglandin receptor antagonist, 5-5751.1 Pharmacol Exp. Ther. (2001) 298(2):411–419.
- MATSUOKA T, HIRATA M, TANAKA H et al.: Prostaglandin D2 as a mediator of allergic asthma. Science (2000) 287(5460): 2013–2017.
- FROICU M, WEAVER V, WYNN TA, MCDOWELL MA, WELSH JE, CANTORNA MT: A crucial role for the vitamin D receptor in experimental inflammatory bowel diseases. Md. EndocrinoL (2003) 17(12):2386–2392.
- WITTKE A, WEAVER V MAHON BD, AUGUST A. CANTORNA MT: Vitamin D receptor-deficient mice fail to develop experimental allergic asthma. J. Immunol. (2004) 173(5):3432–3436.
- BARISH GD, EVANS RM: A nuclear strike against Listeria-the evolving life of LXR. Cell (2004) 119(2):149–151.
- COLLINS JL: Therapeutic opportunities for liver X receptor modulators. Curr. Opin. Drug Disc. Devel (2004) 7(5):692–702.
- •A comprehensive review on LXR receptors as potential drug targets.
- LEFTHERIS K, ARMED G, CHAN R, DYCKMAN AJ, HUSSAIN Zr The Discovery of orally active triaminotriazine aniline amides as inhibitors of p38 MAP kinase.J. Med. Chem. (2004) 47(25):6283–6291.
- STEED PM, TANSEY MG, ZALEVSKY J et al.: Inactivation of TNF signaling by rationally designed dominant-negative TNF variants. Science (2003) 301(5641):1895–1898.
- JABLONOWSKI JA, GRICE CA, CI-JAI W et al.: The first potent and selective non-imidazole human histamine H4 receptor antagonists. J. Med. Chem. (2003) 46(19):3957–3960.
- THURMOND RL, DESAI PJ, DUNFORD PJ et al.: A potent and selective histamine H4 receptor antagonist with anti-inflammatory properties. Pharmacol Exp. Ther. (2004) 309(1):404–413.
- REITER LA, ROBINSON RP, MCCLURE KF et al.: Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1. Bioorg-. Med. Chem. Lett. (2004) 14(13):3389–3395.
- REITER LA, MITCHELL PG, MARTINELLI GJ, LOPRESTI-MORROW LL, YOCUM SA, ESKRA JD: Phosphinic acid-based MMP-13 inhibitors that spare MMP-1 and MMP-3. Bioorg-. Med. Chem. Lett. (2003) 13(14):2331–2336.
- RANDLE JC, HARDING MW, KU G, SCHONHARTING M, KURRLE R: ICE/Caspase-1 inhibitors as novel anti-inflammatory drugs. Expert Opin. Investig Drugs (2001) 10(7):1207–1209.
- •Although a few years old, this is a nice review covering the rationale behind ICE inhibitors and the development of pralanacasan.
- FANTUZZI G, DINARELLO CA: Interleukin-18 and interleukin-1 beta: two cytokine substrates for ICE (caspase-1). Clin. Immunol (1999) 19(1):1–11.